Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
HYPAQUE SODIUM 20% is a diagnostic contrast agent administered via ureteral route as a solution for imaging procedures. It is a legacy radiographic contrast medium used primarily in urologic and renal imaging to visualize the urinary tract and assess renal function. The drug works by absorbing X-rays differentially, allowing visualization of urinary system structures.
A mature, legacy diagnostic product with LOE approaching; commercial teams are likely focused on transition planning and line extension rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job openings suggest minimal active hiring for this product line. Working on HYPAQUE SODIUM 20% represents a stable but declining career opportunity with GE HealthCare's diagnostic portfolio, suitable for professionals seeking portfolio management experience rather than growth-oriented roles.
Worked on HYPAQUE SODIUM 20% at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.